OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity. OcuTerra a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current st...
OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity. OcuTerra a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch and wait” does not prevent or control the progression of disease
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.